Abstracts Archive - Page 2256 of 2607 - ACR Meeting Abstracts

Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…
Abstract Number: 2664 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Osteoporosis Medication Starts In Patients Based On T-Score and FRAX® Absolute Fracture Risk Model In a Large Health Care System
Robert A. Overman^1,2 and Chad L. Deal³, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: The National Osteoporosis Foundation (NOF) 2008 guidelines recommend treatment for postmenopausal women (PMW) and men ≥ 50 if the T-score is ≤-2.5 at the…
Abstract Number: 2665 • 2013 ACR/ARHP Annual Meeting
Efficiency Gains For Rheumatology Consultation From An Electronic Referral System In a Safety Net Health System
Meghan M. Scheibe¹, John B. Imboden², Gabriela Schmajuk³, Mary Margaretten⁴, Jonathan D. Graf⁵, Alice Chen³, Edward H. Yelin⁶ and Jinoos Yazdany³, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Div Of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatology care is a scarce resource in some settings. Health information technology holds promise in increasing the quality and efficiency of rheumatology referrals, but…
Abstract Number: 2666 • 2013 ACR/ARHP Annual Meeting
Implementing a Personalized Health Plan To Improve Therapeutic Outcomes In Veterans With Gout
Astrud Lorraine Leyva¹, Una E. Makris² and Salahuddin Kazi³, ¹Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX, ²Rheumatology, UT Southwestern Medical Center, VA Medical Center, Dallas, TX, ³Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX
Background: Gout is a chronic crystal-induced arthritis that predominantly occurs among men with rising prevalence with advancing age. Patients with uncontrolled gout present with recurrent…
Abstract Number: 2667 • 2013 ACR/ARHP Annual Meeting
Fast-Track Pathway In Giant Cell Arteritis: A Cost-Effectivenss Analysis
Katerina Achilleos¹, Pravin Patil¹, Win Win Maw¹, Laura Bown², David Halsall², Charles Dobson², Christian Dejaco³, Frances Borg¹, Sunil Gupta⁴ and Bhaskar Dasgupta¹, ¹Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ²Department Of Health, National Health Service England, Leeds, United Kingdom, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Castlepoint and Rochford, Clinical Commissioning Group, Southend-on-sea, United Kingdom
Background/Purpose: With incidence of 2.2 per 10,000 patient years, it is estimated that 12,000 new cases of Giant Cell Arteritis (GCA) are diagnosed every…
Abstract Number: 2668 • 2013 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, An Intra-Articular (IA) Sustained-Release Formulation Of Triamcinolone Acetonide (TCA), To An Approved Injectable Suspension Of TCA In Patients With Osteoarthritis (OA) Of The Knee
Neil Bodick¹, Joelle Lufkin¹, Christina Willwerth¹, Pierre Lachance², Gregory Jasey³, Anil Gupta⁴, Anthony Chris⁵, Marc Russo⁶, Michael O'Mahony⁷, Sam Henein⁸, Louise Murdoch⁹, Ferdinandus de Looze¹⁰, David Hunter¹¹ and Michael Clayman¹, ¹Flexion Therapeutics, Burlington, MA, ²Clinique St-Louis (Recherche) Inc, Quebec, QC, Canada, ³North Walkerville Orthopaedic Associates, Windsor, ON, Canada, ⁴Anil K. Gupta Medicine Professional Corporation, Toronto, ON, Canada, ⁵Aim Health Group, Waterloo, ON, Canada, ⁶Hunter Clinical Research, Broadmeadow, Australia, ⁷London Road Diagnostic Clinic and Medical Centre, Sarnia, ON, Canada, ⁸SKDS Research Inc., Newmarket, ON, Canada, ⁹Emeritus Research, Malvern East, Australia, ¹⁰AusTrials Pty Limited, Sherwood, Australia, ¹¹Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: FX006 is a novel sustained-release formulation of TCA in poly(lactic-co-glycolic) acid microspheres intended to maintain therapeutic concentrations in the joint up to 3 months…
Abstract Number: 2669 • 2013 ACR/ARHP Annual Meeting
Treatment Of Knee Osteoarthritis Patients With Strontium Ranelate Reduces The Loss Of Cartilage Volume and Bone Marrow Lesions As Assessed By Magnetic Resonance Imaging: Data From The Phase III Strontium Ranelate Efficacy In Knee Osteoarthrtis Trial
Johanne Martel-Pelletier¹, Camille Roubille¹, Jean-Pierre Raynauld¹, François Abram², Marc Dorais³, Philippe Delorme¹ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada
Background/Purpose: This study aimed to evaluate in a subpopulation of osteoarthritis (OA) patients from the SEKOIA Phase III trial the disease-modifying (DMOAD) effect of strontium…
Abstract Number: 2670 • 2013 ACR/ARHP Annual Meeting
Does Change In Femorotibial Cartilage Thickness Differ Between Acutely Anterior-Cruciate Ligament Injured Knees Treated With and Without Reconstructive Surgery
Wolfgang Wirth¹, Felix Eckstein¹, Martin Hudelmaier², Stefan Lohmander³ and Richard Frobell⁴, ¹Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ²Paracelsus Medical University, Salzburg, Austria, ³Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: An ACL tear is a serious knee injury, involving chronic alterations in joint biomechanics. The risk of developing knee OA after an ACL tear…
Abstract Number: 2671 • 2013 ACR/ARHP Annual Meeting
The Relationship Between Toe-Out Angle During Walking and Risk Of Medial Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis Study
K. Douglas Gross¹, Yuqing Zhang¹, Emily K. Quinn², Michael C. Nevitt³, Neil A. Segal⁴, Cora E. Lewis⁵ and David T. Felson¹, ¹Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University, Boston, MA, ³Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁴Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁵Preventive Medicine, University of Alabama, Birmingham, Birmingham, AL
Background/Purpose: A previous study suggests a linear relationship between increased toe-out angle during walking and reduced risk of medial knee OA progression. Yet, gait lab…
Abstract Number: 2672 • 2013 ACR/ARHP Annual Meeting
Associations Between Popliteal Artery Wall Thickness and Knee Structure In Adults Without Clinical Knee Disease: A Prospective Cohort Study
Yuanyuan Wang¹, Diaz Novera¹, Anita Wluka², Jessica Fairley¹, Graham Giles³, Richard O'Sullivan⁴, Andrew Teichtahl⁵ and Flavia Cicuttini², ¹Monash University, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³University of Melbourne, Melbourne, Australia, ⁴Epworth Hospital, Melbourne, Australia, ⁵Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: There is evidence for a vascular contribution to the pathogenesis of osteoarthritis. The aim of this study was to examine the association between popliteal…
Abstract Number: 2673 • 2013 ACR/ARHP Annual Meeting
Mortality In Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With The General Population
Aleksandra Turkiewicz¹, Tuhina Neogi², George Peat³ and Martin Englund⁴, ¹Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Research Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: There is strong evidence in support of increased mortality in patients with rheumatoid arthritis (RA), while the relation is more controversial in osteoarthritis (OA).…
Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Angela B. Robinson¹, Vin Tangpricha², Eric Yow³, Reut Gurion⁴, Grace McComsey⁴ and Laura E. Schanberg⁵, ¹Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Pediatrics, Duke University Medical Center, Durham, NC
Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
Abstract Number: 2635 • 2013 ACR/ARHP Annual Meeting
IgA Vasculitis In Adults – a Rare and Benign Disease?
Alojzija Hocevar¹, Jaka Ostrovrsnik¹, Vesna Jurcic² and Matija Tomsic^3,4, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Institute of Pathology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ⁴Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia
Background/Purpose: IgA vasculitis (IgAV) is the most common vasculitis in children, with a defined epidemiology (14 cases/ 105children), clinical picture and generally favourable prognosis. In…
Abstract Number: 2636 • 2013 ACR/ARHP Annual Meeting
IgA Vasculitis – The Second Most Common Systemic Vasculitis In Adults In Slovenia
Alojzija Hocevar¹, ŽIga Rotar¹, Jaka Ostrovrsnik¹, Vesna Jurcic², Jelka Lindic³ and Matija Tomsic^4,5, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Institute of Pathology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ³Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ⁵Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia
Background/Purpose: IgA vasculitis (IgAV) is assumed to be rare in adults. Reported annual incidence rates vary between 0.8 and 1.8 cases per 100,000 adults.1 Our…
Abstract Number: 2637 • 2013 ACR/ARHP Annual Meeting
Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis
Luca Quartuccio¹, Miriam Isola², Laura Corazza³, Soledad Retamozo⁴, Manal Abdel-Moneim El-Menyawi⁵, Elisa Gremese⁶, Marco Sebastiani⁷, Nicolo Pipitone⁸, Teresa Urraro⁹, Vincenza Conteduca¹⁰, Christos Koutsianas¹¹, Benjamin Terrier¹², Mostafa Naguib Zoheir¹³, Alessandra Ghinoi¹⁴, Davide Filippini¹⁵, Francesco Saccardo¹⁶, Mohamed Nabil Salem¹⁷, Salvatore Scarpato¹⁸, Paolo Fraticelli¹⁹, Antonio Tavoni²⁰, Eleonora Catarsi²¹, Cesare Mazzaro²², Pietro Pioltelli²³, Mervat Matar⁵, Patrizia Scaini²⁴, Matija Tomsic²⁵, Norihiro Nishimoto^26,27, Dimitrios Vassilopoulos²⁸, Michael Voulgarelis²⁹, Gaafar M. Ragab³⁰, Carlo Salvarani³¹, Armando Gabrielli³², Patrice Cacoub³³, Loic Guillevin³⁴, Domenico Sansonno³⁵, Anna Linda Zignego³⁶, Gianfranco Ferraccioli⁶, Athanasios G. Tzioufas³⁷, Manuel Ramos-Casals³⁸, Clodoveo Ferri³⁹, Maurizio Pietrogrande⁴⁰, Giuseppe Monti¹⁶, Massimo Galli⁴¹, Stefano Bombardieri⁴² and Salvatore De Vita⁴³, ¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ²Institute of Statistics, DSMB, University of Udine, Udine, Italy, ³Rheumatology Clinic, University of Udine, Udine, Italy, ⁴Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁵Faculty of Medicine, Cairo, Egypt, ⁶Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁷Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁸Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁹Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Department of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy, ¹¹Department of Pathophysiology, Medical School of Athens, Athens, Greece, ¹²Internal Medicine, Cochin University Hospital, Paris, France, ¹³Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ¹⁵Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, ¹⁶Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, ¹⁷Faculty of Medicine, Beni Swafe University, Beni Swafe, Egypt, ¹⁸Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, ¹⁹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ²⁰University of Pisa, Immunoallergology Unit, Pisa, Italy, ²¹Department of Internal Medicine, Section of Immunoallergology, University of Pisa, Pisa, Italy, ²²Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy, ²³Hematology, S.Gerardo Hospital, Monza, Italy, ²⁴Nephrology, Spedali Civili di Brescia, Brescia, Italy, ²⁵Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ²⁶Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ²⁷Osaka Rheumatology Clinic, Osaka, Japan, ²⁸2nd Department of Medicine, Athens University School of Medicine, Athens, Greece, ²⁹School of Medicine, University, Department of Pathophysiology, Athens, Greece, ³⁰Int Medicine Hosp/Rheum&Immun, Faculty of Medicine, Cairo University, Giza, Egypt, ³¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³²Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ³³Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, ³⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ³⁵Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Medical School, Bari, Italy, ³⁶University of Florence, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁷Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ³⁸Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ³⁹Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴⁰Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, ⁴¹Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy, ⁴²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴³Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: preliminary Classification Criteria for cryoglobulinemic vasculitis (CV) have been developed in 2011 by an European cooperative study, with an adequate methodology in a large…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].